Sutro Biopharma Inc
NASDAQ:STRO
US |
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
|
US |
Estee Lauder Companies Inc
NYSE:EL
|
Consumer products
|
|
US |
Exxon Mobil Corp
NYSE:XOM
|
Energy
|
|
US |
Church & Dwight Co Inc
NYSE:CHD
|
Consumer products
|
|
US |
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
|
US |
American Express Co
NYSE:AXP
|
Financial Services
|
|
US |
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
|
US |
Visa Inc
NYSE:V
|
Technology
|
|
CN |
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
|
US |
3M Co
NYSE:MMM
|
Industrial Conglomerates
|
|
US |
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
|
US |
Coca-Cola Co
NYSE:KO
|
Beverages
|
|
US |
Target Corp
NYSE:TGT
|
Retail
|
|
US |
Walt Disney Co
NYSE:DIS
|
Media
|
|
US |
Mueller Industries Inc
NYSE:MLI
|
Machinery
|
|
US |
PayPal Holdings Inc
NASDAQ:PYPL
|
Technology
|
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
52 Week Range |
2.28
5.65
|
Price Target |
|
We'll email you a reminder when the closing price reaches USD.
Choose the stock you wish to monitor with a price alert.
Johnson & Johnson
NYSE:JNJ
|
US | |
Estee Lauder Companies Inc
NYSE:EL
|
US | |
Exxon Mobil Corp
NYSE:XOM
|
US | |
Church & Dwight Co Inc
NYSE:CHD
|
US | |
Pfizer Inc
NYSE:PFE
|
US | |
American Express Co
NYSE:AXP
|
US | |
Nike Inc
NYSE:NKE
|
US | |
Visa Inc
NYSE:V
|
US | |
Alibaba Group Holding Ltd
NYSE:BABA
|
CN | |
3M Co
NYSE:MMM
|
US | |
JPMorgan Chase & Co
NYSE:JPM
|
US | |
Coca-Cola Co
NYSE:KO
|
US | |
Target Corp
NYSE:TGT
|
US | |
Walt Disney Co
NYSE:DIS
|
US | |
Mueller Industries Inc
NYSE:MLI
|
US | |
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
This alert will be permanently deleted.
Intrinsic Value
The intrinsic value of one STRO stock under the Base Case scenario is 3.87 USD. Compared to the current market price of 3.58 USD, Sutro Biopharma Inc is Undervalued by 7%.
The Intrinsic Value is calculated as the average of DCF and Relative values:
Valuation Backtest
Sutro Biopharma Inc
Uncover deeper insights with the Valuation Backtest. Learn how current stock valuations stack up against historical averages to gauge true investment potential.
Start backtest now and learn if your stock is truly undervalued or overvalued!
Stock is trading at its lowest valuation over the past 5 years.
To access the results of this valuation backtest, please register an account with us. Registration is quick and gives you instant access to insights on 3 stocks per week for free.
The backtest for STRO cannot be conducted due to limitations such as insufficient data or other constraints. Please select a different stock or adjust your settings.
Fundamental Analysis
Select up to 3 indicators:
Select up to 3 indicators:
Months
Months
Months
Months
Select up to 2 periods:
Revenue & Expenses Breakdown
Sutro Biopharma Inc
Balance Sheet Decomposition
Sutro Biopharma Inc
Current Assets | 443.5m |
Cash & Short-Term Investments | 426m |
Receivables | 7m |
Other Current Assets | 10.5m |
Non-Current Assets | 45.6m |
PP&E | 39.7m |
Other Non-Current Assets | 5.8m |
Current Liabilities | 130m |
Accounts Payable | 6.1m |
Accrued Liabilities | 49.9m |
Other Current Liabilities | 74m |
Non-Current Liabilities | 206.9m |
Other Non-Current Liabilities | 206.9m |
Earnings Waterfall
Sutro Biopharma Inc
Revenue
|
169.4m
USD
|
Operating Expenses
|
-275.5m
USD
|
Operating Income
|
-106.1m
USD
|
Other Expenses
|
-18.3m
USD
|
Net Income
|
-124.4m
USD
|
Free Cash Flow Analysis
Sutro Biopharma Inc
USD | |
Free Cash Flow | USD |
STRO Profitability Score
Profitability Due Diligence
Sutro Biopharma Inc's profitability score is 18/100. The higher the profitability score, the more profitable the company is.
Score
Sutro Biopharma Inc's profitability score is 18/100. The higher the profitability score, the more profitable the company is.
STRO Solvency Score
Solvency Due Diligence
Sutro Biopharma Inc's solvency score is 42/100. The higher the solvency score, the more solvent the company is.
Score
Sutro Biopharma Inc's solvency score is 42/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
STRO Price Targets Summary
Sutro Biopharma Inc
According to Wall Street analysts, the average 1-year price target for STRO is 12.24 USD with a low forecast of 5.05 USD and a high forecast of 21 USD.
Dividends
Current shareholder yield for STRO is .
Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?
Profile
Country
Industry
Market Cap
Dividend Yield
Description
Sutro Biopharma Inc. engages in the drug discovery, development and manufacture of pharmaceutical products. The company is headquartered in South San Francisco, California and currently employs 224 full-time employees. The company went IPO on 2018-09-27. The company is focused on deploying its integrated cell-free protein synthesis and site-specific conjugation platform, XpressCF, to create a variety of protein therapeutics, initially for cancer. The company is engaged in designing therapeutics using potent modalities, including cytokine-based therapeutics, immuno-oncology agents, antibody-drug conjugates (ADCs) and bispecific antibodies that are directed against clinically validated targets. Its product candidate includes STRO-002 and STRO-001. STRO-002, is an ADC directed against folate receptor-alpha, for patients with FolRα-expressing cancers, such as ovarian and endometrial cancers. STRO-001, is an ADC directed against CD74, for patients with B-cell malignancies, such as multiple myeloma and non-Hodgkin lymphoma. Its product candidates are designed and optimized for therapeutic index by placing linker-warheads at specific locations within the antibody.
Contact
IPO
Employees
Officers
The intrinsic value of one STRO stock under the Base Case scenario is 3.87 USD.
Compared to the current market price of 3.58 USD, Sutro Biopharma Inc is Undervalued by 7%.